Authenticity of probiotic foods and dietary supplements: A pivotal issue to address
Related Experiment Video
Updated: Nov 10, 2025

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods
Published on: September 10, 2016
Vincenzina Fusco1, Francesca Fanelli1, Daniele Chieffi1
1National Research Council of Italy, Institute of Sciences of Food Production (CNR-ISPA), Bari, Italy.
Abstract:
The market of probiotic foods and supplements is growing rapidly but frequently the commercialized products are not compliant with their labels in terms of claimed probiotic strain(s) and labeled number of viable probiotic cells, thus mining the authenticity of these probiotic products.In this review, we provide an up-to-date overview of: (i) the current regulatory aspects, (ii) the consistency of probiotic foods and supplements with their labels, (iii) the implications of mislabeling on the quality, safety and functionality of these products and (iv) the available and most promising methods to assess the authenticity of these products, taking into account the need to discriminate among the different physiological states probiotics might be in the carrier matrices. It arises that authenticity of probiotic foods and supplements is an urgent issue, of industrial and legislation relevance, that need to be addressed. A plethora of methods are available to reach this goal, each with its own advantages and disadvantages. Protocols that combine the use of propidium monoazide (PMA) with metagenomics or polyphasic approaches including the PMA real time PCR or flow cytometry (for the viability assessment) and the whole genome sequence analysis (for the identification and typing of the probiotic strain) are the most promising that should be standardized and used by producers and regulators.
More Related Videos
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Microorganisms in Agriculture and Food industry
Need for Obtaining Pure Cultures
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

